This phase II/III study is assessing cobolimab in combination with dostarlimab and docetaxel as a second-line treatment for advanced NSCLC following disease progression after anti-PD-1/PD-L1 therapies. The gene discussed is CD274; the disease is non-small cell lung carcinoma.